- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05799157
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
June 25, 2024 updated by: Veradermics, Inc.
Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Protocol 250-12951-201 is a planned Phase 2 study entitled "A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris".
Eligible subjects will be randomized into one of the three treatment groups (high dose, low dose, vehicle).
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Katie Mateja, MBA
- Phone Number: 448-949-1411
- Email: kmateja@therapeuticsinc.com
Study Locations
-
-
Arkansas
-
Fort Smith, Arkansas, United States, 72916
- Recruiting
- Site 07
-
-
California
-
San Diego, California, United States, 92123
- Recruiting
- Site 16
-
-
Indiana
-
Plainfield, Indiana, United States, 46168
- Recruiting
- Site 02
-
-
Kentucky
-
Louisville, Kentucky, United States, 40241
- Recruiting
- Site 13
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Recruiting
- Site 15
-
-
Minnesota
-
New Brighton, Minnesota, United States, 55112
- Recruiting
- Site 09
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- Recruiting
- Site 01
-
Greenville, South Carolina, United States, 29615
- Recruiting
- Site 06
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
- Recruiting
- Site 11
-
-
Texas
-
Arlington, Texas, United States, 76011
- Recruiting
- Site 03
-
Austin, Texas, United States, 78759
- Recruiting
- Site 04
-
College Station, Texas, United States, 77845
- Recruiting
- Site 10
-
Houston, Texas, United States, 77056
- Recruiting
- Site 12
-
Pflugerville, Texas, United States, 78660
- Recruiting
- Site 05
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Recruiting
- Site 14
-
-
Washington
-
Spokane, Washington, United States, 99202
- Recruiting
- Site 08
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject is a male or non-pregnant female, 9 to 65 years of age.
- Subject has provided written informed consent/assent.
- Females must be post-menopausal, surgically sterile, or use an effective method of birth control. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Baseline.
- Subject has at least 1 and up to 8 common warts (verruca vulgaris),
- Subject is willing to undergo test article therapy as directed, comply with study instructions (including availability to a smart phone or equivalent device for telehealth visit requirements), and commit to all follow-up visits for the duration of the study.
- Subject is in good general health and free of any disease state or physical condition that might impair evaluation of the identified warts and/or treatment area or exposes the subject to an unacceptable risk by study participation.
Exclusion Criteria:
- Subject is pregnant, lactating, or is planning to become pregnant during the study.
- Subject used or will use oral zinc and/or cimetidine within 30 days prior to enrollment or during the course of the study.
- Subject has received 3 or more prior treatments to the Target Lesion without resolution.
Subject received any of the following therapies within the specified wash-out period prior to Baseline in the treatment area of the Target Lesion
- LASER, light or other energy-based therapy (e.g., intense pulsed light [IPL], PDT; 12 weeks
- Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester [SADBE], etc.), retinoids, hydrogen peroxide; 12 weeks
- Cryotherapy, biopsy, electrodessication, curettage, antimetabolite therapy (e.g., 5- fluorouracil), cantharidin, or any other treatment that in the opinion of the Investigator may affect the Target Lesion; 6 weeks
- Over-the-counter (OTC) wart therapies, paring ± occlusion; 1 week
- Subject has scars, tattoos, or other features that may interfere with the evaluation of the Target Lesion, in the opinion in the investigator.
- Subject has a significant autoimmune condition or is immunocompromised based on their medical condition (e.g., HIV, malignancy, etc.), medication use, or other factors. Routine use of inhaled, intranasal or ophthalmologic corticosteroids during the study is allowed.
- Subject has received systemic immunosuppressive therapy such as steroids, methotrexate, cyclosporine, tacrolimus, chemotherapy, etc. within in 4 weeks prior to Baseline.
- Subject has any active malignancy or are undergoing treatment for any malignancy other than nonmelanoma skin cancer;
- Subject has history of significant ophthalmologic inflammatory disease, including uveitis.
- Subject is currently enrolled in an investigational drug, biologic, or device study.
- Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to Visit 1/Baseline.
- Subject has a history of allergy or sensitivity to this antigen extract or similar products.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group A (Low Dose)
Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed.
There may be up to 6 treatments (approximately 1 per month).
|
Microneedle patch containing 125 mcg of active drug
|
Experimental: Treatment Group B (High Dose)
High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed.
There may be up to 6 treatments (approximately 1 per month).
|
Microneedle patch containing 250 mcg of active drug
|
Placebo Comparator: Treatment Group C (Vehicle)
Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed.
There may be up to 6 treatments (approximately 1 per month).
|
Placebo microneedle patch containing no active drug (i.e., placebo)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment period
Time Frame: Baseline up to Day 134
|
Complete clinical resolution is defined as the target lesion with area = 0.
|
Baseline up to Day 134
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with complete clinical resolution of Target Lesion by visit
Time Frame: Days 22, 43, 64, 85, 106, and 134
|
Days 22, 43, 64, 85, 106, and 134
|
Proportion of subjects with complete clinical resolution of all the Non-Target Lesion(s) by visit
Time Frame: Days 22, 43, 64, 85, 106, and 134
|
Days 22, 43, 64, 85, 106, and 134
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 28, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
March 22, 2023
First Submitted That Met QC Criteria
March 22, 2023
First Posted (Actual)
April 5, 2023
Study Record Updates
Last Update Posted (Actual)
June 27, 2024
Last Update Submitted That Met QC Criteria
June 25, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 250-12951-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warts
-
RXi Pharmaceuticals, Corp.UnknownPlantar Warts | Common Warts | HPV (Human Papillomavirus) | Periungual WartsUnited States
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Karo Pharma ABCompletedPlantar Wart | Common WartPoland
-
Nielsen BioSciences, Inc.Recruiting
-
Swiss Footcare Laboratories - Poderm ProfessionalRecruitingWarts | Plantar Wart | Common WartTunisia
-
Assistance Publique - Hôpitaux de ParisRecruitingPalmar or Plantar WartsFrance
-
MediGeneCharité Research Organisation GmbHCompletedGenital Warts | Perianal WartsGermany
-
Dermax SAbioRASI, LLCCompletedExternal Anogenital WartsRussian Federation, United States, Ukraine
-
G&E Herbal Biotechnology Co., LTDCompletedGenital Warts | Condylomata Acuminata | Condyloma Acuminata | Venereal WartsTaiwan
Clinical Trials on VDMN-21 Patch Low Dose
-
NobelpharmaCompletedCytomegalovirus DiseaseUnited States, Japan
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Hypersensitivity, Immediate | Peanut HypersensitivityUnited States
-
Vaxxas Pty LtdBiomedical Advanced Research and Development AuthorityNot yet recruiting
-
Coloplast A/SCompleted
-
HvivoPfizerRecruiting
-
University of ZurichCompleted
-
The University of Texas Health Science Center at...CompletedNeuropathic Pain | Spinal Cord InjuriesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico